CD274 and non-small cell lung carcinoma: Cells with morphologies consistent with all these cell types were found to express variable PD-L1 labeling intensities in our tissue sections classified as pattern I, II and V. Moreover, these PD-L1 expressing cells have been previously shown to be therapeutically important, as positive responses to Atezolizumab were enriched in NSCLC when PD-L1 was expressed by infiltrating immune cells [31].